Published by Gbaf News
Posted on June 12, 2018

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Gbaf News
Posted on June 12, 2018

Improving the accuracy and user-friendliness of mass spec technologies to enable critical decisions in safety, healthcare and nutrition
SINGAPORE – Media OutReach – 07 June 2018 – SCIEX, a global leader in life science analytical technologies, has announced today that it will highlight a suite of recent innovations for streamlining biotherapeutics research and development, as well as its latest technologies for delivering accessible, high performance clinical diagnostics, at ASMS 2018.
These developments have been optimized for maximal sensitivity, accuracy and efficiency for scientists using challenging workflows in critical fields, without sacrificing robustness or ease of use.
Recent additions to the SCIEX biopharma portfolio:
New OS software:
Earlier this year, SCIEX also announced several other new technologies. These include the Citrine™ MS/MS System for clinical diagnostics, delivering highly sensitive and rapid quantification of large panels of molecules, as well as the OptiFlow Interface and C100HT Biologics Analyzer.
“These latest developments reflect the SCIEX commitment to improving the future of science and, ultimately, well-being,” said Inese Lowenstein, President, SCIEX. “By making mass spec more sensitive, robust and user-friendly, we’re enabling analysts and clinicians to make critical decisions with enhanced accuracy, while improving their lab productivity and reducing costs.”
SCIEX will showcase its pioneering technologies throughout ASMS at booth #601 and at the SCIEX Hospitality and Demo Suite, at the Hilton Bayfront. In addition, scientists from SCIEX will provide a series of Users Meetings and Breakfast Seminars, as well as present numerous talks and posters during the ASMS Technical Program. For more information, please visit sciex.com/events/ASMS2018.
Improving the accuracy and user-friendliness of mass spec technologies to enable critical decisions in safety, healthcare and nutrition
SINGAPORE – Media OutReach – 07 June 2018 – SCIEX, a global leader in life science analytical technologies, has announced today that it will highlight a suite of recent innovations for streamlining biotherapeutics research and development, as well as its latest technologies for delivering accessible, high performance clinical diagnostics, at ASMS 2018.
These developments have been optimized for maximal sensitivity, accuracy and efficiency for scientists using challenging workflows in critical fields, without sacrificing robustness or ease of use.
Recent additions to the SCIEX biopharma portfolio:
New OS software:
Earlier this year, SCIEX also announced several other new technologies. These include the Citrine™ MS/MS System for clinical diagnostics, delivering highly sensitive and rapid quantification of large panels of molecules, as well as the OptiFlow Interface and C100HT Biologics Analyzer.
“These latest developments reflect the SCIEX commitment to improving the future of science and, ultimately, well-being,” said Inese Lowenstein, President, SCIEX. “By making mass spec more sensitive, robust and user-friendly, we’re enabling analysts and clinicians to make critical decisions with enhanced accuracy, while improving their lab productivity and reducing costs.”
SCIEX will showcase its pioneering technologies throughout ASMS at booth #601 and at the SCIEX Hospitality and Demo Suite, at the Hilton Bayfront. In addition, scientists from SCIEX will provide a series of Users Meetings and Breakfast Seminars, as well as present numerous talks and posters during the ASMS Technical Program. For more information, please visit sciex.com/events/ASMS2018.